跳至主要内容
临床试验/NCT06096168
NCT06096168已完成不适用

Ambispective Study Evaluating the Clinical Results of SAGITTA EVL R Revision Stems

Societe dEtude, de Recherche et de Fabrication1 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2023年4月13日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
42
试验地点
1
主要终点
Survival Rate at Mid Term Follow-up

研究概览

简要总结

This clinical study is conducted to collect data on hip arthroplasty with the SAGITTA EVL-R revision femoral stems manufactured by SERF. In order to reflect current practice, a comprehensive and continuous series of patients will be included.

This study will confirm the performance and safety of the SAGITTA EVL R revision femoral stems within the framework of MDR 2017/745 and in relation to the recommendations of the MEDDEV guide 2.7.1. Rev 4 (Clinical Evaluation Guide), which provides for a systematic procedure to monitor clinical data in order to verify the claimed performance of medical devices.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient over 18 years old at the time of surgery,
  • Patient implanted with a SAGITTA EVL R revision femoral stem within its indications between 01/01/2016 and 31/12/2018,
  • Affiliated to French health insurance system

排除标准

  • Patient who has not expressed consent for data collection and participation in the study,
  • Patient unable to understand the surgeon's instructions or to perform postoperative follow-up.
  • Patient with a contraindication to the use of the SAGITTA EVL R revision femoral stem
  • Patient implanted with a SAGITTA EVL R revision femoral stem outside its indication

结局指标

主要结局

Survival Rate at Mid Term Follow-up

时间窗: Between 4 to 7 years after surgery

Assess the survival rate, at least 4 year-follow-up, whatever the cause of revision. Cumulative survival rate expressed in percentage of implants not revised (remaining in place) using Kaplan Meier calculation.

次要结局

  • Adverse Events(From per operative period to 4/6 years after surgery)
  • Survival Rates at Mid Term Follow-up (by Component)(At 4/6 years after surgery)
  • Survival Rates at Mid Term Follow-up (by Etiology)(At 4/6 years after surgery)
  • Patient's Satisfaction(At 4/6 years after surgery)
  • Oblivion of Prosthesis(At 4/6 years after surgery)
  • Functional Improvement(At 4/6 years after surgery)

研究者

发起方
Societe dEtude, de Recherche et de Fabrication
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验